Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
5
Not yet recruiting, industry sponsors, Immunology and inflammation, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed251
5 trials
Showing 1 to 5, recently updated first.
- A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisNot yet recruiting
SanofiSanofi (SNY)
NCT07905547 · 56 participants (planned) · Start Oct 28, 2026 · Primary completion Feb 7, 2027
Drug: Dupilumab · For: Atopic Dermatitis
- Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative ColitisPivotal-lookingNot yet recruiting
Bausch Health Americas, Inc.Industry
NCT05976802 · 100 participants (planned) · Start Jun 2029 · Primary completion Jun 2030
Drug: High dose budesonide rectal foam; Low dose budesonide rectal foam and 1 more · For: Ulcerative Colitis
- A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque PsoriasisNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07529925 · 30 participants (planned) · Start May 2026 · Primary completion Apr 2028
Drug: Adalimumab Solution for Injection · For: Severe Plaque Psoriasis in Chinese Children
- Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative ColitisNot yet recruiting
Rubix LSIndustry
NCT07059130 · 150 participants (planned) · Start Jul 16, 2025 · Primary completion Jan 1, 2026
Drug: Mirikizumab · For: Crohn Disease (CD); Crohns Disease; Ulcerative Colitis (UC)
Sites: Lawrence, Massachusetts
- Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque PsoriasisNot yet recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06779097 · 1,564 participants (planned) · Start Feb 2025 · Primary completion Mar 2027
Drug: Vunakizumab (IL-17A inhibitor) · For: Moderate to Severe Plaque Psoriasis
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.